OR Stock Analysis: LOréal S.A. | PA
Household & Personal Products | PA, France | Market Cap: 204.787m EUR | 12M Return: 0.9% | FR0000120321 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 105M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LOréal S.A. is a French-headquartered global cosmetics manufacturer operating through four reporting divisions: Professional Products, Consumer Products, Luxe, and Dermatological Beauty. Its product portfolio spans skincare, make-up, hair colourants, haircare, perfume, and hygiene, sold under a large house-of-brands strategy that ranges from mass-market labels such as LOréal Paris, Garnier, and Maybelline New York to prestige and luxury lines such as Lancôme, Yves Saint Laurent Beauté, Kiehls, and Aesop, plus dermatologist-positioned brands including La Roche-Posay, CeraVe, and Vichy. Founded in 1909 and listed in Paris, the group sells across virtually every major region, from Europe and North America to Asia-Pacific, the Middle East, Africa, and Latin America.
The company sits in the Consumer Staples sector, Personal Care Products sub-industry, and earns revenue through a highly diversified multi-channel distribution model covering hair salons, pharmacies and drugstores, mass-market retail, department store perfumeries, free-standing stores, travel retail, and e-commerce, allowing it to serve consumers across price tiers and category entry points. This combination of a broad brand portfolio spanning mass to luxury, a presence across professional, retail, and digital channels, and globally balanced geographic exposure is characteristic of large-scale personal care players.
- North Asia luxury demand weakness pressures Luxe division growth
- Dermatological Beauty segment drives margin expansion via CeraVe and La Roche-Posay
- Travel retail recovery remains uncertain amid Chinese consumer caution
| Net Income: 6.31b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -2.18 > 1.0 |
| NWC/Revenue: -1.27% < 20% (prev 8.64%; Δ -9.91% < -1%) |
| CFO/TA 0.14 > 3% & CFO 8.99b > Net Income 6.31b |
| Net Debt (15.0b) to EBITDA (11.0b): 1.37 < 3 |
| Current Ratio: 0.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (535.4m) vs 12m ago -0.18% < -2% |
| Gross Margin: 76.64% > 18% (prev 73.31%; Δ 3.33% > 0.5%) |
| Asset Turnover: 75.00% > 50% (prev 60.98%; Δ 14.02% > 0%) |
| Interest Coverage Ratio: 20.35 > 6 (EBIT TTM 9.03b / Interest Expense TTM 443.8m) |
| A: -0.01 (Total Current Assets 18.0b - Total Current Liabilities 18.5b) / Total Assets 66.4b |
| B: 0.35 (Retained Earnings 23.4b / Total Assets 66.4b) |
| C: 0.15 (EBIT TTM 9.03b / Avg Total Assets 60.5b) |
| D: 1.04 (Book Value of Equity 33.8b / Total Liabilities 32.5b) |
| Altman-Z'' = 3.19 = A |
| DSRI: 0.74 (Receivables 6.75b/6.70b, Revenue 45.4b/33.3b) |
| GMI: 0.96 (GM 73.31% / 76.64%) |
| AQI: 1.13 (AQ_t 0.63 / AQ_t-1 0.56) |
| SGI: 1.36 (Revenue 45.4b / 33.3b) |
| TATA: -0.04 (NI 6.31b - CFO 8.99b) / TA 66.4b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of September 14, 2026, the stock is trading at EUR 379.85 with a total of 298,706 shares traded. Over the past week, the price has changed by -1.05%, over one month by -1.00%, over three months by -0.90% and over the past year by +0.90%.
Current recommended Stop Loss: 365.90 (which is 3.7% or 1.7 ATR below the current price).
LOréal S.A. has no consensus analysts rating.
P/E Trailing = 32.6251
P/E Forward = 25.3807
P/S = 4.5174
P/B = 5.9577
P/EG = 2.3047
Revenue TTM = 45.4b EUR
EBIT TTM = 9.03b EUR
EBITDA TTM = 11.0b EUR
Long Term Debt = 9.79b EUR (from longTermDebt, last quarter)
Short Term Debt = 4.99b EUR (from shortTermDebt, last quarter)
Debt = 19.1b EUR (from shortLongTermDebtTotal, last quarter) + Leases 2.38b
Net Debt = 15.0b EUR (calculated: Debt 19.1b - CCE 4.05b)
Enterprise Value = 220b EUR (205b + Debt 19.1b - CCE 4.05b)
Interest Coverage Ratio = 20.35 (Ebit TTM 9.03b / Interest Expense TTM 443.8m)
EV/FCF = 29.14x (Enterprise Value 220b / FCF TTM 7.54b)
FCF Yield = 3.43% (FCF TTM 7.54b / Enterprise Value 220b)
FCF Margin = 16.63% (FCF TTM 7.54b / Revenue TTM 45.4b)
Net Margin = 13.90% (Net Income TTM 6.31b / Revenue TTM 45.4b)
Gross Margin = 76.64% ((Revenue TTM 45.4b - Cost of Revenue TTM 10.6b) / Revenue TTM)
Gross Margin QoQ = 74.77% (prev 78.70%)
Tobins Q-Ratio = 3.31 (Enterprise Value 220b / Total Assets 66.4b)
Interest Expense / Debt = 2.33% (Interest Expense 443.8m / Debt 19.1b)
Taxrate = 27.67% (2.42b / 8.73b)
NOPAT = 6.53b (EBIT 9.03b * (1 - 27.67%))
Current Ratio = 0.97 (Total Current Assets 18.0b / Total Current Liabilities 18.5b)
Debt / Equity = 0.56 (Debt 19.1b / totalStockholderEquity, last quarter 33.8b)
Debt / EBITDA = 1.37 (Net Debt 15.0b / EBITDA 11.0b)
Debt / FCF = 1.99 (Net Debt 15.0b / FCF TTM 7.54b)
Total Stockholder Equity = 33.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.43% (Net Income 6.31b / Total Assets 66.4b)
RoE = 18.95% (Net Income TTM 6.31b / Total Stockholder Equity 33.3b)
RoCE = 20.98% (EBIT 9.03b / Capital Employed (Equity 33.3b + L.T.Debt 9.79b))
RoIC = 12.93% (NOPAT 6.53b / Invested Capital 50.5b)
WACC = 5.95% (E(205b)/V(224b) * Re(6.35%) + D(19.1b)/V(224b) * Rd(2.33%) * (1-Tc(0.28)))
Discount Rate = 6.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.56 | Cagr: -0.19%
[DCF] Terminal Value 75.70% ; FCFF base≈7.49b ; Y1≈7.64b ; Y5≈8.36b
[DCF] Fair Price = 215.0 (EV 130b - Net Debt 15.0b = Equity 114b / Shares 532.4m; r=8.35% [WACC [floored]]; 5y FCF grow 1.95% → 2.50% )
EPS Correlation: -63.47 | EPS CAGR: -2.38% | SUE: N/A | # QB: 0
Revenue Correlation: 12.94 | Revenue CAGR: 2.14% | SUE: 1.23 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=13.64 | Chg30d=-1.19% | Revisions=-29% | GrowthEPS=+7.3% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=14.90 | Chg30d=-0.33% | Revisions=+10% | GrowthEPS=+9.3% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: -10% (up=16, down=20)